Zimmerman, M.A., Haskins, K., Bradley, B., Gilman, J., Gamboni-Robertson, F. and Flores, S.C. (2011) Autoimmune-mediated vascular injury occurs prior to sustained hyperglycemia in a murine model of type I diabetes mellitus. J. Surg Res (In Press).
Delong, T., Reisdorph, N., Reisdorph, R., Powell, R.L., Armstrong, M., Baker, R.L., Barbour, G., Bradley, B., and Haskins, K. (2011) Islet amyloid polypeptide is the autoantigen for a diabetogenic CD4 T cell clone BDC-5.2.9. Diabetes. (Provisionally accepted)
Delong, T., Reisdorph, N., Reisdorph, R., Powell, R.L., Armstrong, M., Baker, R.L., Barbour, G., Bradley, B., and Haskins, K. (2011) Islet amyloid polypeptide is the autoantigen for a diabetogenic CD4 T cell clone BDC-5.2.9. Diabetes 60: 2325-30.
Haskins, K. and Cooke, A. (2011) CD4 T cells and their antigens in the pathogenesis of autoimmune diabetes. Curr Opin in Immunol 23: 739-45.
Baker, R.L., Mallevaey, T., Gapin, L. and Haskins, K. (2012) T cells interact with T cells via CD40-CD154 to promote autoimmunity in T1D. Eur. J. Immunol.42: 672-80.
Nakayama, M., Castoe, T., Sosinowski, T., He, XL., Johnson, K., Haskins, K., Vignali, D.A.A., Gapin, L., David Pollock, D., and Eisenbarth, G.S. 2012. Germline T cell receptor sequences target the primary insulin peptide for NOD type 1 diabetes. Diabetes 61: 857-65.
Hume, P.S., He, J., Haskins, K., and Anseth, K.S. 2012. Strategies to reduce dendritic cell activation through functional biomaterial design. Biomaterials 33: 3615-25.
Delong, T., Baker, R.L., He, J., Barbour, G., Bradley, B., and Haskins, K. 2012. Diabetogenic T cell clones recognize an altered peptide of Chromogranin A. Diabetes (Revision in review).
Delong, T., Baker, R.L., He, J., and Haskins, K. 2013. Novel autoantigens for diabetogenic CD4 T cells in autoimmune diabetes. Immunologic Res. 55: 167-72. PMCID: PMC3713226.
Cordova, K.C., Willis, V.C., Haskins, K., and Holers, V.M. A Citrullinated Fibrinogen-Specific T Cell Line Enhances Autoimmune Arthritis In a Mouse Model of Rheumatoid Arthritis. 2013. J. Immunol. 190: 1457-65.
Baker, R.L., Delong, T., Barbour, G., Bradley, B., Nakayama, M. and Haskins, K. 2013. Cutting Edge: CD4 T cells reactive to a peptide from IAPP accumulate in the pancreas of NOD mice. J. Immunol.191: 3990-4. PMCID: PMC3815676
Gottlieb, P.A., Delong, T., Baker, R.L., Fitzgerald-Miller, L., Wagner, R., Cook, G., Rewers, M.J., Michels, A. and Haskins, K. 2013. Chromogranin A is a T Cell Antigen in Human Type 1 Diabetes. J. Autoimmunity, (In Press)
Kyewski, B. and Haskins, K. 2012. The classical dicihotomy between presentation of endogenous antigens via the MHC class-I pathway and exogenous antigens via the MHC class-II pathway. Curr Opin in Immunol 24: 67-70.
Delong, T., Baker, R.L., He, J., Barbour, G., Bradley, B., and Haskins, K. 2012. Diabetogenic T cell clones recognize an altered peptide of Chromogranin A. Diabetes 61: 3239-46.
Gottlieb, P.A., Delong, T., Baker, R.L., Fitzgerald-Miller, L., Wagner, R., Cook, G., Rewers, M.J., Michels, A. and Haskins, K. 2014. Chromogranin A is a T Cell Antigen in Human Type 1 Diabetes. J. Autoimmunity 50: 38-41.
General parity between trio and pairwise breeding of laboratory mice in static caging.
Kedl RM, Wysocki LJ, Janssen WJ, Born WK, Rosenbaum MD, Granowski J, Kench JA, Fong DL, Switzer LA, Cruse M, Huang H, Jakubzick CV, Kosmider B, Takeda K, Stranova TJ, Klumm RC, Delgado C, Tummala S, De Langhe S, Cambier J, Haskins K, Lenz LL, Curran-Everett D.
J Immunol. 2014 Nov 15;193(10):4757-60
Time to look back and to look forward.
Nair KS, Abel ED, Adler SG, Dyck PJ, Gardner TW, Haskins KM, Hotamisligil G, Jensen MD, Krook A, Mandarino LJ, Mitchell BD, Pessin JE, Sowers JR, Sussel L, Wareham N, Vella A.
Diabetes. 2014 Apr;63(4):1169-70.
Delong, T., Baker, R.L., He, J., and Haskins, K. 2013. Novel autoantigens for diabetogenic CD4 T cells in autoimmune diabetes. Immunologic Res. 55: 167-72.
Cordova, K.C., Willis, V.C., Haskins, K., and Holers, V.M. A Citrullinated Fibrinogen-Specific T Cell Line Enhances Autoimmune Arthritis In a Mouse Model of Rheumatoid Arthritis. 2013. J. Immunol. (In press, Epub Jan 2013).
Lindsay, R.S., Corbin, K., Mahne, A., Levitt, B.E., Gebert, M.J., Wigton, E.J., Bradley, B.J., Haskins, K., Jacobelli, J., Tang, Q., Krummel, M.F., Friedman, R.S. 2015. Antigen recognition in the islets changes with progression of autoimmune islet infiltration J. Immunol.194: 522-30.
Viret, C., Mahiddine, K., Baker, R., Haskins, K. and Guerder, S. 2015. The T cell repertoire diversifying enzyme TSSP contributes to thymic selection of diabetogenic CD4 T cell specificities reactive to ChgA and IAPP autoantigens. J. Immunol.195: 1964-73.
Baker, R.L., Bradley, B., Wiles, T.A., Lindsay, R.S., Barbour, G., Delong, T., Friedman, R.S. and Haskins, K. 2016. NOD mice deficient in chromogranin A do not develop diabetes. J. Immunol Cutting Edge, In Press.
Delong, T., Wiles, T.A., Baker, R.L., Bradley, B., Barbour, G., Reisdorph, R., Armstrong, M., Powell, R.L., Reisdorph, N., Kumar, N., Elso, C.M., DeNicola, M., Bottino, R., Powers, A.C., Harlan, D.M., Kent, S.C., Mannering, S.I. and Haskins, K. 2016. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science, In Press.
Baker, R.L., Delong, T., Barbour, G., Bradley, B., and Haskins, K. 2013. CD4 T cells reactive to a peptide from IAPP accumulate in the pancreas of NOD mice. (Submitted)
Baker, R.L., Bradley, B., Wiles, T.A., Lindsay, R.S., Barbour, G., Delong, T., Friedman, R.S. and Haskins, K. 2016. NOD mice deficient in chromogranin A do not develop diabetes. J. Immunol Cutting Edge 196: 39-43.
Delong, T., Wiles, T.A., Baker, R.L., Bradley, B., Barbour, G., Reisdorph, R., Armstrong, M., Powell, R.L., Reisdorph, N., Kumar, N., Elso, C.M., DeNicola, M., Bottino, R., Powers, A.C., Harlan, D.M., Kent, S.C., Mannering, S.I. and Haskins, K. 2016. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science 351: 711-14.
Haskins, K. and Buckner, J.H. 2016. Editorial overview: Autoimmunity. Curr. Opin. Immunol. In Press.
Babon, J.A., DeNicola, M.E., Blodgett, D.M., Crèvecoeur, I., Buttrick, T.S., Maehr, R., Bottino, R., Naji, A., Kaddis, J., Elyaman, W., James, E.A., Haliyur, R., Brissova, M., Overbergh, L., Mathieu, C., Delong, T., Haskins, K., Pugliese, A., Campbell-Thompson, M., Mathews, C., Atkinson, M.A., Powers, A.C., Harlan, D.M., Kent, S.C. 2016. Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes. Nat Med. In Press.
Wiles, A.T., Delong, T., Baker, R.L., Barbour, G., Powell, R., Bradley, B., Reisdorph, N. and Haskins, K. 2016. An insulin-IAPP hybrid peptide is an endogenous antigen for CD4 T cells in the non-obese diabetic mouse. J. Autoimmun. In press.
Babon JAB, DeNicola ME, Blodgett DM, Crèvecoeur I, Buttrick TS, Maehr R, Bottino R, Naji A, Kaddis J, Elyaman W, James EA, Haliyur R, Brissova M, Overbergh L, Mathieu C, Delong T, Haskins K, Pugliese A, Campbell-Thompson M, Mathews C, Atkinson MA, Powers AC, Harlan DM, Kent SC. Corrigendum: Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes. Nat Med. 2017 Aug 4;23(8):1004. PubMed PMID: 28777787
Wiles TA, Delong T, Baker RL, Bradley B, Barbour G, Powell RL, Reisdorph N, Haskins K. An insulin-IAPP hybrid peptide is an endogenous antigen for CD4 T cells in the non-obese diabetic mouse. J Autoimmun. 2017 Mar;78:11-18. PubMed PMID: 27802879
Baker, R.L., Jamison, B.L., Wiles, T.A., Lindsay, R.S., Barbour, G., Bradley, B., Delong, T., Friedman, R.S., Nakayama, M. and Haskins. K. 2018. CD4 T cells reactive to hybrid insulin peptides are indicators of disease activity in the NOD mouse. Diabetes 67: 1836-46.
Jamison, B.L. and Haskins, K. 2018. Tissue crosstalk in T1D: Is insulin special? Immunity 49: 394-6.
Wiles, T.A., Powell, R., Michel, C.R., Beard, K.S., Hohenstein, A., Bradley, B., Reisdorph, N., Haskins, K. and Delong, T. 2018 (Web Pub). Identification of hybrid insulin peptides (HIPs) in mouse and human islets by mass spectrometry. J. Proteome Research. In press.
Wiles, T.A., Powell, R., Michel, C.R., Beard, K.S., Hohenstein, A., Bradley, B., Reisdorph, N., Haskins, K. and Delong, T. 2019. Identification of hybrid insulin peptides (HIPs) in mouse and human islets by mass spectrometry. J. Proteome Research. 18: 814-25.
Sandor, A.M., Lindsay, R.S., Dyjack, N., Whitesell, J.C., Rios, C., Bradley, B.J., Haskins, K., Serreze, D.V., Guerts, A., Chen, Y.-G., Seibold, M.A., Jacobelli, J. and Friedman, R.S. 2019. CD11c+ cells are gatekeepers f¬¬or lymphocyte trafficking to infiltrated islets during Type 1 Diabetes. Frontiers in Immunology. 10: 1-17.
Dirice, E., Kahraman, S., De Jesus, D.F., Ouaamari, A.E., Basile, G., Baker, R.L., Yigit, B., Piehowski, P.D., Kim, M.J., Dwyer, A.J., Ng, R.W.S., Schuster, C., Vethe, H., Martinov, T., Ishikawa, Y., Teo, A.K.K., Smith, R.D., Hu, J., Haskins, K., Serwold, T., Qian, W.-J., Fife, B.T., Kissler, S. and Kulkarni, R.N. 2019. Increased ß-cell proliferation before immune-cell invasion
prevents progression of type 1 diabetes. Nature Metab. 1: 509-18.
Jamison, B.L., Neef, T., Goodspeed, A., Bradley, B., Baker, R.L., Miller, S.D. and Haskins, K. 2019. Nanoparticles Containing an Insulin-ChgA Hybrid Peptide Protect from Transfer of Autoimmune Diabetes by Shifting the Balance between Effector T cells and Tregs. J. Immunol. 203: 48-57.
Baker, R.L., Rihanek, M., Hohenstein, A.C., Nakayama, M., Rewers, M.J., Michels, A. Gottlieb, P.A., Haskins, K. and Delong, T. 2019. T cells reactive to hybrid insulin peptides are present in PBMC of patients with type 1 diabetes. Diabetes 68: 1830-40.
Baker, R.L., Jamison, B.L. and Haskins, K. 2019. Hybrid Insulin Peptides are Neo-epitopes for CD4 T cells in Autoimmune Diabetes. Curr Opin in Endocrinol Diabetes Obes 26: 195-200.
Sandor, A.M., Lindsay, R.S., Dyjack, N., Whitesell, J.C., Rios, C., Bradley, B.J., Haskins, K., Serreze, D.V., Guerts, A., Chen, Y.-G., Seibold, M.A., Jacobelli, J. and Friedman, R.S. 2019. CD11c+ cells are gatekeepers f¬¬or lymphocyte trafficking to infiltrated islets during Type 1 Diabetes. Frontiers in Immunology. In Press.
Arribas-Layton, D., Guyer, P., Delong, T., Dang, M., Chow, I.-T., Speake, C., Greenbaum, C., Kwok, W.W., Baker, R.L., Haskins, K. and James, E.A. 2020. Hybrid Insulin Peptides are recognized by Human T cells in the context of DRB1*04:01. Diabetes 69: 1492-1502.
Dai, Y.D., Dias, P., Margosiak, A., Marquardt, K., Bashratyan, R., Hu, W.-Y., Haskins, K. and Evans, L.H. 2020. Endogenous retrovirus Gag antigen and its gene variants are unique autoantigens expressed in the pancreatic islets of non-obese diabetic mice. Immunol Lett. 223: 62-70.
Haskins, K. and Wenzlau, J. 2020. CD4 T Cells and Neo-Antigens in Autoimmune Diabetes. Critical Reviews in Immunology.
Dilisio, J.E. and Haskins, K. 2021. Induction of Antigen-Specific Tolerance in Autoimmune Diabetes with Nanoparticles containing Hybrid Insulin Peptides. Biomedicines 9:240.
Wiles, T.A., Hohenstein, A., Landry, L.G., Dang, M., Powell, R., Guyer, P., James, E.A., Nakayama, M., Haskins, K., Delong, T. and Baker, R.L. 2021. Characterization of human CD4 T cells specific for a C-peptide/C-peptide hybrid insulin peptide. Frontiers in Immunology 12.
Srivastava, N., Hu, H., Vomund, A.N., Peterson, O.J., Baker, R.L., Haskins, K., Teyton, L., Wan, X. and Emil R. Unanue, E.R. 2021. Chromogranin A deficiency confers protection from autoimmune diabetes via multiple mechanisms. Diabetes: 70:2860-70.
Jamison, B.L., DiLisio, J.E., Beard, K.S., Neef, T., Bradley, B., Goodman, J., Gill, R.G., Miller, S.D., Baker, R.L. and Haskins, K. 2021. Tolerogenic Delivery of a Hybrid Insulin Peptide Markedly Prolongs Islet Graft Survival in the Non-Obese Diabetic (NOD) Mouse. Diabetes. (In press)
Jamison, B.L., DiLisio, J.E., Beard, K.S., Neef, T., Bradley, B., Goodman, J., Gill, R.G., Miller, S.D., Baker, R.L. and Haskins, K. 2022. Tolerogenic Delivery of a Hybrid Insulin Peptide Markedly Prolongs Islet Graft Survival in the Non-Obese Diabetic (NOD) Mouse. Diabetes 71: 483-96.
Wenzlau, J.M., Dilisio J.E., Barbour, G., Dang, M., Hohenstein, A.C., Nakayama, M., Delong, T., Baker, R.L. and Haskins, K. 2022. Insulin B-chain hybrid peptides are agonists for InsB:9-23-reactive T cells in autoimmune diabetes. Front. Immunol. 13: 926650.
Crawford, S.A., Wiles, T.A., Wenzlau, J.M., Powell, R.L., Barbour, G., Dang, M., Groegler, J., Barra, J.M., Burnette, K.S., Hohenstein, A.C., Baker, R.L., Tse, H.M., Haskins, K. and Delong, T. 2022. Cathepsin D drives the formation of Hybrid Insulin Peptides relevant to the pathogenesis of Type 1 Diabetes. Diabetes 71: 2793-2803.
Identification of Autoantibodies to a Hybrid Insulin Peptide in Type 1 Diabetes.
Wenzlau JM, Gu Y, Michels A, Rewers M, Haskins K, Yu L.
Diagnostics (Basel). 2023 Sep 4;13(17):2859. doi: 10.3390/diagnostics13172859.
PMID: 37685398
Hybrid insulin peptide isomers spontaneously form in pancreatic beta-cells from an aspartic anhydride intermediate.
Crawford SA, Groegler J, Dang M, Michel C, Powell RL, Hohenstein AC, Reyes K, Haskins K, Wiles TA, Delong T.
J Biol Chem. 2023 Nov;299(11):105264. doi: 10.1016/j.jbc.2023.105264. Epub 2023 Sep 19.
PMID: 37734557
An Insulin-Chromogranin A hybrid peptide activates DR11 restricted T cells in human type 1 diabetes. Callebaut, A., Guyer, P., Baker, R.L., Hohenstein, A., Gottlieb, P.A., Mathieu, C., Overbergh, L., Haskins, K. and Eddie A. James, E.A. 2024. Diabetes. In Press.
Wenzlau JM, Peterson OJ, Vomund AN, DiLisio JE, Hohenstein A, Haskins K, Wan X. Mapping of a hybrid insulin peptide in the inflamed islet ß-cells from NOD mice. Front Immunol. 2024;15:1348131. PubMed PMID: 38455055
Callebaut A, Guyer P, Baker RL, Gallegos JB, Hohenstein AC, Gottlieb PA, Mathieu C, Overbergh L, Haskins K, James EA. An Insulin-Chromogranin A Hybrid Peptide Activates DR11-Restricted T Cells in Human Type 1 Diabetes. Diabetes. 2024 May 1;73(5):743-750. PubMed PMID: 38295386
Hohenstein, A.C., Gallegos, J., Dang, M., Groegler, J., Broncucia, H., Tensun, F., Waugh, K., Dong, F., James, E.A., Speake, C., Steck, A., Rewers, M.J., Gottlieb, P.A., Haskins, K., Delong, T. and Baker, R.L. 2024. Novel T cell reactivities to hybrid insulin peptides in autoantibody-positive subjects and type 1 diabetes patients. Diabetes In Press